Friday 6 November 2026
Export PRPH’s income statement to Excel — free account
ProPhase Labs, Inc.
PRPH Healthcare Diagnostics & Research
ProPhase Labs, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $4.3 million, down 35.8% from fiscal 2024.
- Revenue
- −18.9%
- EPS
- +80.0%
- Free cash flow
- +56.7%
- Total debt
- +19.4%
Quarter to June 2026, against a year earlier
0.01
0.00
0.00%
Follow PRPH
Alert me
| Older periods | Sep '25 | Dec '25 | Mar '26 | Jun '26 | |
|---|---|---|---|---|---|
Piotroski F-Score |
+8 more TTM periods Free account |
3 | 4 | 4 | 3 |
| (185.40%) | (271.49%) | (331.81%) | (543.95%) | ||
| (52.95%) | (23.96%) | (44.22%) | (45.53%) | ||
ROIC |
(220.98%) | (122.44%) | (203.72%) | (387.30%) | |
Return on Tangible Assets |
92.34% | 30.78% | 46.92% | 42.01% | |
Average Days of Receivables |
237.12 | 129.03 | 166.04 | 178.45 | |
Free Cash Flow per Share |
(2.54) | (0.37) | (0.46) | (0.39) | |
Free Cash Flow |
(10.55) | (8.22) | (5.63) | (5.53) | |
Capital Expenditures |
0.08 | 0.12 | 0.08 | 0.01 | |
| Other line items | |||||
Cash ROIC |
(114.88%) | (87.56%) | (106.79%) | (214.34%) | |
Accounts Receivable Turnover |
0.29 | 0.40 | 0.31 | 0.29 | |
Accounts Payable Turnover |
0.14 | 0.11 | 0.09 | 0.09 | |
Inventory Turnover |
1.92 | 4.88 | 3.90 | 5.86 | |
Average Days of Payables |
3,754.80 | 4,999.92 | 6,436.61 | 5,998.92 | |
Days of Inventory on Hand |
23.87 | 8.63 | 10.79 | 9.68 | |
Tax Rate |
0.37 | 0.00 | 0.73 | 0.09 | |
Research and Development Expense of Revenue |
3.30% | 0.00% | 0.00% | 0.00% | |
Selling, General and Administrative Expense of Revenue |
602.00% | 444.74% | 530.78% | 514.92% | |
Share Based Compensation of Revenue |
41.09% | 43.57% | 51.95% | 51.62% | |
Interest Coverage |
(7.28) | (2.60) | (2.41) | (2.17) | |
Operating CF/Net income |
0.25 | 0.57 | 0.24 | 0.24 | |
Depreciation/Fixed assets |
3.43 | 5.07 | 5.71 | 6.87 | |
Capex/Depreciation |
0.01 | 0.01 | 0.01 | 0.00 | |
Revenue per Share |
1.22 | 0.20 | 0.28 | 0.23 | |
Operating CF per Share |
(2.56) | (0.38) | (0.46) | (0.40) | |
Capex per Share |
0.02 | 0.01 | 0.01 | 0.00 | |
Capex to Sales |
(0.02) | (0.03) | (0.02) | 0.00 |
Columns are period end dates · fundamentals updated 26 Oct 2026